StealthX™ Vaccine Platform

About Capricor Therapeutics

Capricor Therapeutics is dedicated to advancing a new class of medicines using its core expertise in cardiosphere-derived cells (CDCs) and exosome science. The company is on the cusp of a potential regulatory milestone with Deramiocel for DMD, supported by positive late-breaking HOPE-3 trial data. Beyond its lead program, Capricor is building a broader pipeline through its StealthX™ platform, targeting the delivery of oligonucleotides, proteins, and small molecules, positioning it at the forefront of precision-engineered exosome therapeutics.

Therapeutic Areas